Novartis AG stock (CH0012005267): Vanrafia Phase III data highlight kidney drug progress

Novartis AG shares traded near recent levels on SIX as the Swiss group reported final 2.5-year Phase III ALIGN data for its IgA nephropathy drug Vanrafia, showing a substantially slower decline in kidney function versus placebo and sustained proteinuria reductions, according to a company update on 06/04/2026.

Novartis AG shares on the SIX Swiss Exchange traded broadly in line with recent levels on 06/04/2026 as the Swiss healthcare group highlighted final 2.5-year Phase III ALIGN study results for its kidney disease therapy Vanrafia in adults with IgA nephropathy, according to a company media release dated 06/04/2026 and cited by Novartis.

In its Basel announcement on 06/04/2026, Novartis reported that Vanrafia (atrasentan) slowed the decline of kidney function by about 34% versus placebo over 2.5 years in the Phase III ALIGN trial, based on an analysis of the estimated glomerular filtration rate (eGFR) slope, while also delivering sustained reductions in proteinuria through the end of treatment, according to Novartis as of 06/04/2026.

For investors in Switzerland, the stock continues to be traded primarily on SIX under the ticker NVSN and in Swiss francs, while Novartis is also listed in the United States via American depositary shares on the NYSE under the ticker NVS, providing additional liquidity for international investors.

As of: 06/04/2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: Novartis
• Sector/industry: Pharmaceuticals and biotechnology
• Headquarters/country: Basel, Switzerland
• Core markets: Europe, United States, Asia-Pacific
• Key revenue drivers: Innovative prescription medicines across oncology, cardiovascular, immunology and neuroscience
• Home exchange/listing venue: SIX Swiss Exchange (NOVN)
• Trading currency: CHF

Novartis AG: core business model

Novartis focuses on researching, developing and marketing patented prescription medicines, with growth tied largely to the uptake and pricing of its innovative therapies in major markets such as Europe and the United States.

Industry trends and competitive position

The global biopharmaceutical industry has been seeing heightened interest in specialty therapies targeting kidney disease, and Novartis is positioning itself within this niche through Vanrafia for IgA nephropathy, supported by the final 2.5-year Phase III ALIGN data reported by the company on 06/04/2026, where the drug reduced the rate of kidney function decline by about 34% versus placebo based on eGFR slope analysis, according to Novartis as of 06/04/2026.

Beyond efficacy on kidney function, Novartis highlighted that Vanrafia cut protein levels in the urine by 38.3% compared with placebo at nine months in the ALIGN study, with reductions maintained through the end of treatment over 2.5 years, giving the group a differentiated profile in IgA nephropathy and reinforcing its broader strategy to focus on high-value specialty medicines, according to the same 06/04/2026 company update.

Conclusion

For shareholders in Novartis AG, the detailed Phase III ALIGN results released on 06/04/2026 add more quantitative evidence around the kidney benefits of Vanrafia in IgA nephropathy, including a roughly 34% slower decline in kidney function versus placebo and a 38.3% reduction in proteinuria at nine months, as reported by Novartis as of 06/04/2026.

How these data points translate into future regulatory, reimbursement and commercial developments for Vanrafia, and how they interact with the wider kidney-disease treatment landscape and the group’s strategic emphasis on high-value specialty drugs, will likely shape market perceptions of Novartis AG over the medium term.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.